Search

EHA2022 Gallery

Thank you to the Faculty, delegates, and industry partners for contributing to the EHA2022 Hybrid Congress.

Read more

For mentors

When discussing this career development opportunity with your associates, please keep in mind that applicants with the same mentor are eligible to apply. However, no more than ONE participant from a specific mentor will be selected.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Research trainings

Old ways won't open new doors. Via non-pecuniary awards, EHA strives to accelerate the careers of promising post-docs in translational or clinical research.

Read more